Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1995-01-19
2000-11-07
Draper, Garnette D.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
530351, 53038822, 53038921, 530402, 435 691, 435 695, 4352523, 4353201, 536 235, 930140, 514 2, 514 8, 424 851, 935 10, C07K 14705, C12N 100
Patent
active
061438669
ABSTRACT:
At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from urine is disclosed. The deglycosylated form of the 3O kDa TNF inhibitor and 40 kDa TNF inhibitor are described as being active against TNF. The 40 kDa TNF inhibitor is active against both TNF alpha a TNF beta. The amino acid sequence of the 30 kDa TNF inhibitor and the 40 kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4560649 (1985-12-01), Saxena et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4609546 (1986-09-01), Hiratani et al.
patent: 4675285 (1987-06-01), Clark et al.
patent: 4760067 (1988-07-01), Firestone
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw et al.
patent: 4931544 (1990-06-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4966888 (1990-10-01), Saxena et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5446090 (1995-08-01), Harris
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5569779 (1996-10-01), Sabahi et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5695953 (1997-12-01), Wallach et al.
Beutler and Cerami (1989), The Biology of Cachectin/TNF-A Primary Mediator of the Host Response, Ann. Rev. Immunol., 7:625-655.
Aggarwal et al., "Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by .gamma.-Interferon," Nature 318:665-667 (1985).
Baglioni et al., "Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition," J. Biol. Chem. 260(25):13395-13397 (1985).
Bakouche et al., "Plasma Membrane-Associated Tumor Necrosis Factor, A Non-Integral Membrane Protein Possibly Bound to Its Own Receptor," J. Immunol. 140:1142-1147 (1988).
Beutler et al., "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science 229:869-871 (1985).
Binkert et al., "Cloning, Sequence Analysis and Expression of a cDNA Encoding a Novel Insulin-like Growth Factor Binding Protein (IGFBP-2)," The EMBO J. 8(9):2497-2502 (1989).
Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, 247:1306-1310 (1990).
Brennan et al., Lancet, vol. 2 (8657), pp. 244-247 (1989).
Brockhaus et al., "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies," Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990).
Capaldi et al., "Changes in Order of Migration of Polypeptides in Complex III and Cytochrome c Oxidase under Different Conditions of SDS Polyacrylamide Gel Electrophoresis," Biochem. & Biophys. Res. Comm. 74(2):425-433 (1977).
Carlino et al., "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF Proteins", J. Biol. Chem. 262(3):958-961 (1987).
Colletti et al., "The Production of Tumor Necrosis Factor Alpha and the Development of a Pulmonary Capillary Injury Following Hepatic Ischemia/Reperfusion," Transplantation 49(2):268-272 (1990).
Creasey et al., "A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated with Cytotoxicity," Proc. Natl. Acad. Sci. USA 84:3293-3297 (1987).
Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor .alpha. Inhibitor," Chemical Abstracts 113(38760n):454 (1990).
Dembic et al., "Two Human TNF Receptors Have Similar Extracellular, But Distinct Intracellular, Domain Sequences," Cytokine 2(4):231-237 (1990).
Englemann et al., "A Tumor Necrosis Factor-Binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," J. Biol. Chem. 264(20):11974-11980 (1989).
Englemann et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-Like Activity," J. Biol. Chem. 265(24):14497-14504 (1990).
Englemann et al., "Two Tumor Necrosis Factor-Binding Proteins Purified From Human Urine," J. Biol. Chem. 265(3):1531-1536 (1990).
Espevik et al., "Characterization of Binding and Biological Effects Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor," J. Exp. Med. 171:415-426 (1990).
Evans et al., "The Steroid and Thyroid Hormone Receptor Superfamily," Science 240:889-895 (1988).
Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," Proc. Natl. Acad. Sci. USA 85:8998-9002 (1988).
Gatanaga et al., "Purification and Characterization of an Inhibitor (Soluble Tumor Necrosis Factor Receptor) for Tumor Necrosis Factor and Lymphotoxin Obtained from the Serum Ultrafiltrates of Human Cancer Patients," Proc. Natl. Acad. Sci. USA 87:8781-8784 (1990).
Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," BioTechnology 8:343-346 (1990).
Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor," Molecular and Cell Biology 11(6):3020-3026 (1991).
Gray et al., "Cloning of Human Tumor Necrosis Factor (TNF) Receptor cDNA and Expression of Recombinant soluble TNF-Binding Protein," Proc. Natl. Acad. Sci. USA 87(19):7380-7384 (1990).
Grizzard et al., "Affinity-Labeled Somatomedin-C Receptors and Binding Proteins From the Human Fetus," J. Clin. Endocrinol. & Metab. 58(3):535-543 (1984).
Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," J. Cell. Biochem.Suppl.. 15F:113 (1991).
Hass et al., "Characterization of Specific High Affinity Receptors for Human Tumor Necrosis Factor on Mouse Fibroblasts," J. Biol. Chem. 260(22):12214-12218 (1985).
Hatakeyama et al., "Interleukin-2 Receptor .beta. Chain Gene: Generation of Three Receptor Forms by Cloned Human .alpha. and .beta. Chain cDNA's," Science 244:551-556 (1989).
Hauser et al., "Cytokine Accumulations in CSF of Multiple Sclerosis Patients: Frequent Detection of Interleukin-1 and Tumor Necrosis Factor but not Interleukin-6," Neurology 40:1735-1739 (1990).
Heller et al., "Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected with Epstein-Barr Virus Shuttle Vector cDNA Libraries," J. Biol. Chem. 265(10):5708-5717 (1990).
Heller et al., "Complementary DNA Cloning of a Receptor for Tumor Necrosis Factor and Demonstration of a Shed Form of the Receptor," Proc. Natl. Acad. Sci. USA 87:6151-6155 (1990).
Himmler et al., "Molecular Cloning & Expression of Human & Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein," DNA and Cell Biology 9(10):705-715 (1990).
Hofman et al., "Tumor Necrosis Factor Identified in Multiple Sclerosis Brain," J. Exp. Med. 170:607-612 (1989).
Hohmann et al., "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNF alpha)," J. Biol. Chem. 264(25):14927-14934 (1989).
Israel et al., "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," Immunol. Lett. 12:217-224 (1986).
Kasukabe et al., "Purifi
Brewer Michael T.
Hale Karin K.
King Michael W.
Kohno Tadahiko
Squires Charles
Amgen Inc.
Draper Garnette D.
LandOfFree
Tumor necrosis factor (TNF) inhibitor and method for obtaining t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor necrosis factor (TNF) inhibitor and method for obtaining t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor (TNF) inhibitor and method for obtaining t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1642375